➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Baxter
Dow
Boehringer Ingelheim
Moodys

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

ACCUPRIL Drug Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Which patents cover Accupril, and when can generic versions of Accupril launch?

Accupril is a drug marketed by Pfizer Pharms and is included in one NDA.

The generic ingredient in ACCUPRIL is quinapril hydrochloride. There are eleven drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the quinapril hydrochloride profile page.

Drug patent expirations by year for ACCUPRIL
Drug Prices for ACCUPRIL

See drug prices for ACCUPRIL

Drug Sales Revenue Trends for ACCUPRIL

See drug sales revenues for ACCUPRIL

Recent Clinical Trials for ACCUPRIL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of NebraskaPhase 4
Nova Scotia Health Research FoundationPhase 4
Nova Scotia Health AuthorityPhase 4

See all ACCUPRIL clinical trials

Pharmacology for ACCUPRIL
Paragraph IV (Patent) Challenges for ACCUPRIL
Tradename Dosage Ingredient NDA Submissiondate
ACCUPRIL TABLET;ORAL quinapril hydrochloride 019885

US Patents and Regulatory Information for ACCUPRIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-001 Nov 19, 1991 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-004 Nov 19, 1991 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-002 Nov 19, 1991 AB RX Yes No   Start Trial   Start Trial   Start Trial
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-003 Nov 19, 1991 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ACCUPRIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-004 Nov 19, 1991   Start Trial   Start Trial
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-002 Nov 19, 1991   Start Trial   Start Trial
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-002 Nov 19, 1991   Start Trial   Start Trial
Pfizer Pharms ACCUPRIL quinapril hydrochloride TABLET;ORAL 019885-001 Nov 19, 1991   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Baxter
Dow
Boehringer Ingelheim
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.